Sales of these drugs have soared: imatinib, gefitinib, pivastatin

Source: sebilan 2018-05-29 2017 medical insurance catalog was successfully completed, local policies were put in place, and sales growth of some new varieties initially appeared Today, let's take a look at the changes in the market of some new varieties after entering the medical insurance market ▍ according to statistics, 339 new varieties were added to the medical insurance catalogue in 2017, including 133 varieties of Western medicine, 206 varieties of Chinese patent medicine, and 149 new dosage forms The new varieties and dosage forms are mainly concentrated in the treatment of chronic diseases and major diseases such as hypertension, diabetes and tumor By the end of March 2018, a total of 11 provinces have published the 2017 version of the province's medical insurance catalog Of the remaining 20 provinces, 19 provinces have published and implemented the 2017 version of the national medical insurance catalog, and only Shanxi Province has published the work plan of medical insurance integration and adjustment At present, a total of 31 provinces and autonomous regions have issued documents to incorporate 36 negotiation varieties into the class B management of medical insurance Among them, 10 provinces and regions such as Jiangsu, Guangdong and Jilin have implemented direct online procurement, and the national payment standard for medical insurance has been used as the purchase price, while Shaanxi and Xinjiang have implemented limited price online procurement ▍ entering the medical insurance catalogue, the market is greatly favorable At present, the medical insurance fund is the largest payer in the medical market of China After the drugs are included in the medical insurance catalogue, the proportion of patients at their own expense decreases, and the willingness to use drugs increases, thus driving the terminal sales volume of the hospital As we all know, the adjustment of the medical insurance catalogue in 2009 has led to a significant volume of chronic disease drugs and major disease drugs in the terminal market, such as entecavir, rosuvastatin and tegio According to the data of PDB sample hospitals, the sales scale of entecavir increased from 242 million yuan in 2009 to 1700 million yuan in 2016, with a compound growth rate of 38% in 2009-2014 Figure 1: in 2009, the growth rate of medical insurance catalog was faster (unit: million yuan) Similarly, after the adjustment of medical insurance catalog in 2017, the growth rate of sales of some new varieties in the catalog has also increased significantly For non negotiated varieties, due to the time required for market promotion and the formation of doctors' prescription habits, most of the new varieties are not significantly increased; for a few drugs with excellent efficacy and price sensitive response, the sales growth rate has been significantly increased, such as riluzole, calcium polystyrene sulfonate, minapram, recombinant human type II tumor necrosis factor receptor antibody fusion protein, etc Referring to the volume of products after the adjustment of the medical insurance catalogue in 2009, with the opening of a new round of bidding cycle, it is expected that the sales volume of new varieties will increase significantly in 2018 and 2019 Table 1: Sales and sales growth of new varieties of medical insurance catalogue in 2017